Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis - Summary - MDSpire

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.

  • By

  • March 4, 2026

  • 2 min

Share

Objective:

To track outcomes, safety, and patient experience over time in patients with relapsing multiple sclerosis starting BRUMVI.

Key Findings:
  • The study aims to gather real-world evidence on BRUMVI's performance in everyday clinical practice.
  • Participants must have a confirmed diagnosis of multiple sclerosis and have not received BRUMVI prior to the study.
Interpretation:

The registry will provide insights into the effectiveness and safety of BRUMVI in a real-world setting, complementing findings from randomized trials.

Limitations:
  • Exclusion of patients with recent live vaccinations or active infections.
  • Concurrent participation in interventional MS trials is not allowed.
Conclusion:

This registry offers an opportunity for patients starting BRUMVI to contribute to the understanding of its real-world impact while receiving standard care.

Original Source(s)

Now Enrolling: Real-World Registry Study of BRUMVI (Ublituximab-xiiy) in Relapsing Multiple Sclerosis

  • by

  • March 4, 2026

Related Content

NPs Top US Jobs List Again

The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.

Inflammatory bowel disease therapies and demyelinating diseases: a practical guide to therapeutic benefit and risk

Nuclear receptor PPARγ targets GPNMB to promote oligodendrocyte development and remyelination